Stay updated with breaking news from Bioactive Delivery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A nanogel-based carrier delivering a thyroid hormone-mimicking drug directly to the liver successfully lowered cholesterol levels and reversed obesity in mice.
A University of Massachusetts Amherst biomedical engineer has used a nanogel-based carrier designed in his lab to deliver a drug exclusively to the liver of obese mice, effectively reversing their diet-induced disease.
UMass Amherst Institute for Applied Life Sciences (IALS) startup Cyta Therapeutics was the Judges’ Choice Best Startup at the 16th annual Massachusetts Life Sciences Innovation (MALSI) Day in Boston on July 27.Cyta Therapeutics is an early-stage life
Anna Nagurney: Glad UMass research highlighted Published: 5/14/2021 10:39:51 AM I was delighted to see the “Research breakthrough on cancer” article on the front page of the May 8 edition of the Gazette. The article noting the research conducted at UMass Amherst by faculty and students at the university’s Center for Bioactive Delivery, which has the potential to revolutionize cancer treatment with drugs being delivered to the right cells with fewer side effects, shows the remarkable work being done at UMass Amherst, even in the pandemic. It is very special to see research done “loca...
UMass Amherst researchers achieve breakthrough in the fight against cancer A team of researchers at the Center for Bioactive Delivery at the University of Massachusetts Amherst's Institute for Applied Life Sciences has engineered a nanoparticle that has the potential to revolutionize disease treatment, including for cancer. This new research, which appears today in Angewandte Chemie, combines two different approaches to more precisely and effectively deliver treatment to the specific cells affected by cancer. Two of the most promising new treatments involve delivery of cancer-fighting drugs ...